SCH 58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: Evidence for a functional 'atypical' adenosine A(2A) receptor

European Journal of Pharmacology

Volumn 401, Issue 1, 2000, Pages 63-77

  El Yacoubi, Malika ^a   Ledent, Catherine ^b   Parmentier, Marc ^b   Costentin, Jean ^a   Vaugeois, Jean Marie ^a  

^a IFRMP 23   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adenosine A(2A) receptor; CGS 21680; Knockout, mouse; Motor activity; SCH 58261; ZM 241385

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; HABITUATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PHENETHYLAMINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TIME FACTORS; TRIAZINES; TRIAZOLES;

EID: 0034726038     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00399-X     Document Type: Article

References (64)

1. Acquas E., Wilson C., Fibiger H.C. Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear. J. Neurosci. 16:1996;3089-3096.
2. 2A-adenosine receptor agonists. J. Cardiovasc. Pharmacol. 30:1997;320-324.
3. 2A adenosine receptor in four PC12 cell clones. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;28-32.
4. Barraco R.A., Bryant S.D. Depression of locomotor activity following bilateral injections of adenosine analogs into the striatum of mice. Med. Sci. Res. 15:1987;421-422.
5. 2A receptors in the nucleus accumbens. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;545-553.
6. Belzung C., Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 56:1994;623-628.
7. 2A adenosine receptors on sleep-waking patterns in rats. Drug. Dev. Res. 37:1996;65-72.
8. 2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav. Pharmacol. 7:1996;373-383.
9. Bruns R.F., Fergus G.H., Badger E.W., Bristol J.A., Santay L.A., Hartman J.D., Hays S.J., Huang C.C. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn-Schmiedeberg's Arch. Pharmacol. 335:1987;59-63.
10. 1-mediated hemodynamic effects. J. Pharmacol. Exp. Ther. 268:1994;1506-1511.
11. A receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;261-271.
12. 2A adenosine receptor agonists CGS 21680 and HENECA in the rat hippocampus. Br. J. Pharmacol. 122:1997;1279-1284.
13. 2A receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;295-302.
14. 2 receptor involvement in the hypomobility effects of adenosine analogues in mice. Eur. J. Pharmacol. 168:1989;285-290.
15. Durcan M.J., Morgan P.F. NECA-induced hypomobility in mice: evidence for a predominantly central site of action. Pharmacol. Biochem. Behav. 32:1989;487-490.
16. 2A adenosine receptor antagonists. Psychopharmacology. 148:2000;153-163.
17. 2A receptors. Br. J. Pharmacol. 129:2000;1465-1473.
18. Evoniuk G., Von Borstel R.W., Wurtman R.J. Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl)theophylline. J. Pharmacol. Exp. Ther. 240:1987;428-432.
19. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 26:1997;143-147.
20. 2B receptors. Pharmacol. Rev. 49:1997;381-401.
21. Fredholm B.B. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 76:1995;93-101.
22. Fredholm B.B. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51:1999;83-133.
23. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46:1994;143-156.
24. 1-selective antagonist, DPCPX. Psychopharmacology. 103:1991;541-544.
25. 2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. NeuroReport. 2:1991;139-140.
26. 2A receptor involves activation of both N-and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J. Neurochem. 67:1996;374-381.
27. Haley T.J., Mc Cormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
28. 2A receptors in the nucleus accumbens and the caudate-putamen. Eur. J. Pharmacol. 323:1997;127-131.
29. 2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 251:1989;47-55.
30. 3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 336:1993;57-60.
31. 2-adenosine antagonist in vitro and in vivo. FEBS Lett. 323:1993;141-144.
32. 2 agonist, CGS 21680. Pharmacol. Biochem. Behav. 45:1993;913-919.
33. 2 receptors in rat brain. J. Pharmacol. Exp. Ther. 251:1989;888-893.
34. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology. 34:1995;393-403.
35. 2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 256:1994;263-268.
36. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
37. Katims J.J., Annau Z., Snyder S.H. Interactions in the behavioral effects of methylxanthines and adenosine derivatives. J. Pharmacol. Exp. Ther. 227:1983;167-173.
38. 2A receptor antagonist. Eur. J. Pharmacol. 301:1996;107-113.
39. 2A receptors. Biochem. Pharmacol. 57:1999;65-75.
40. 2A receptor. Nature. 388:1997;674-678.
41. 3H]-CGS 21680 in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;539-541.
42. 1 receptors, using in vivo and in vitro techniques. J. Pharmacol. Exp. Ther. 285:1998;1023-1030.
43. Michael-Titus A., Preterre P., Giros B., Costentin J. Role of endogenous enkephalins in locomotion evidenced by acetorphan, an "enkephalinase" inhibitor. J. Pharmacol. Exp. Ther. 243:1987;1062-1066.
44. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport. 9:1998;3955-3959.
45. 2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J. Pharmacol. Exp. Ther. 259:1991;286-294.
46. 2 receptor antagonist. Eur. J. Pharmacol. 267:1994;335-341.
47. Nörenberg W., Wirkner K., Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Br. J. Pharmacol. 122:1997;71-80.
48. 2A adenosine receptor antagonist. Drug Dev. Res. 42:1997;63-70.
49. 2A receptors. Trends Pharmacol. Sci. 17:1996;364-372.
50. Ongini E., Dionisotti S., Gessi S., Irenius E., Fredholm B.B. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;7-10.
51. Phillis J.W., Barraco R.A., DeLong R.E., Washington D.O. Behavioral characteristics of centrally administered adenosine analogs. Pharmacol. Biochem. Behav. 24:1986;263-270.
52. 2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neurosci. Lett. 251:1998;201-204.
53. Porkka-Heiskanen T. Adenosine in sleep and wakefulness. Ann. Med. 31:1999;125-129.
54. 2A selective adenosine receptor antagonist. Br. J. Pharmacol. 115:1995;1096-1102.
55. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology. 17:1997;82-91.
56. 2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 48:1996;167-189.
57. Simon P., Dupuis R., Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav. Brain Res. 61:1994;59-64.
58. Snyder S.H., Katims J.J., Annau Z., Bruns R.F., Daly J.W. Adenosine receptors and behavioral actions of methylxanthines. Proc. Natl. Acad. Sci. U.S.A. 78:1981;3260-3264.
59. 2/3 receptor agonist on the expression of immediate early genes in globus pallidus. Neuropharmacology. 36:1997;1309-1317.
60. Svenningsson P., Nomikos G.G., Fredholm B.B. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J. Neurosci. 15:1995;7612-7624.
61. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience. 79:1997;753-764.
62. Vaugeois J.-M., Bonnet J.-J., Duterte-Boucher D., Costentin J. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur. J. Pharmacol. 230:1993;195-201.
63. Waldeck B. Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Act. Pharmacol. Toxicol. 36(Suppl. 4):1975;1-23.
64. 2A receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;398-404.